Towards Better Delivery of Cannabidiol (CBD)
Cannabidiol (CBD) has substantial therapeutic potential, but its development as an effective drug by the pharmaceutical industry is hindered by intrinsic characteristics such as low bioavailability, low water solubility, and variable pharmacokinetic profiles. Importantly, lack of patentability of th...
Saved in:
Main Authors: | Sophie Anne Millar (Author), Ryan Francis Maguire (Author), Andrew Stephen Yates (Author), Saoirse Elizabeth O'Sullivan (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
by: Sophie A. Millar, et al.
Published: (2018) -
The use of cannabidiol (CBD) as an analgesic component
by: Kristian Kjær-Staal Petersen, et al.
Published: (2023) -
Strategies to Improve Cannabidiol Bioavailability and Drug Delivery
by: Saoirse Elizabeth O'Sullivan, et al.
Published: (2024) -
The Anti-Inflammatory Effects of Cannabidiol (CBD) on Acne
by: Peyravian N, et al.
Published: (2022) -
Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders
by: Baswan SM, et al.
Published: (2020)